scholarly journals Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Will Evaluating Dose to Coronary Arteries Improve Risk Estimates?

2016 ◽  
Vol 96 (2) ◽  
pp. S126
Author(s):  
E. Hahn ◽  
A. Ng ◽  
S. Bashir ◽  
H. Jiang ◽  
R.W. Tsang ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin Lymphoma ◽  
Coronary Arteries ◽  
Cardiac Toxicity ◽  
Mediastinal Radiation ◽  
Risk Estimates

scholarly journals 61: Does Evaluating Dose to Coronary Arteries Improve Risk Estimates for Late Cardiac Toxicity after Mediastinal Radiotherapy for Hodgkin Lymphoma?

2016 ◽  
Vol 120 ◽  
pp. S24
Author(s):  
Ezra Hahn ◽  
Angela Ng ◽  
Shaheena Bashir ◽  
Haiyan Jiang ◽  
Richard Tsang ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Coronary Arteries ◽  
Cardiac Toxicity ◽  
Risk Estimates

Late cardiac toxicity after mediastinal radiation therapy for Hodgkin’s disease

2004 ◽  
Vol 60 (1) ◽  
pp. S217-S218 ◽  
Author(s):  
J.F. Strasser ◽  
S. Li ◽  
D. Neuberg ◽  
B. Silver ◽  
A.K. Ng ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Cardiac Toxicity ◽  
Hodgkin’S Disease ◽  
Mediastinal Radiation

A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease

Blood ◽  
2010 ◽  
Vol 116 (13) ◽  
pp. 2237-2240 ◽  
Author(s):  
Sten Myrehaug ◽  
Melania Pintilie ◽  
Lingsong Yun ◽  
Michael Crump ◽  
Richard W. Tsang ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Heart Disease ◽  
Hodgkin Lymphoma ◽  
Treatment Options ◽  
Population Based ◽  
Cardiac Morbidity ◽  
Mediastinal Radiation ◽  
Effect Of Treatment ◽  
Competing Risk Models ◽  
Population Based Registry

Abstract The risk of cardiac hospitalization (CH) in Hodgkin lymphoma (HL) patients with preexisting heart disease was evaluated. Patients with HL were identified from a population-based registry (N = 3964). Data were abstracted from records of a randomly selected subcohort (N = 1096). A population-based registry was used to identify CH. Factors associated with CH and the incidence of CH after HL were estimated with competing risk models. Preexisting heart disease was the strongest predictor of posttreatment CH (hazard ratio = 3.98, P < .001) and significantly modified (P = .01) the effect of treatment on the risk of CH. Among patients with preexisting heart disease, treatment with mediastinal radiation therapy plus doxorubicin-based chemotherapy was associated with a 10-year incidence of CH more than 20% higher than treatment with chemotherapy alone. There is a high risk of CH after mediastinal radiation therapy plus doxorubicin-based chemotherapy among patients with preexisting heart disease; this is an important consideration when weighing treatment options, and in the follow-up of these patients.

Sign in / Sign up

Export Citation Format

Share Document